Men with metastatic prostate cancer have a significantly reduced median five‐year survival compared with that associated with the cancer overall. Clinical trials are exploring the most effective treatment strategies for metastatic hormone‐sensitive prostate cancer to intervene before transformation to castration‐resistant prostate cancers when options are limited.
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.